FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN, L2
Executive VP Samantha Pearce to Retire from Jazz Pharmaceuticals
Amendment to Credit Agreement for U.S. Dollar Term Loan B-2 Facility
Completes Acquisition of Actio Biosciences
Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases
FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
Jazz Pharmaceuticals Enters Merger Agreement with Actio Biosciences
To Acquire, Expanding Rare Epilepsy Portfolio
Second Quarter 2026 Financial Results Announced
Q2
Q1
Amended Annual Report
FY 2024
Q3
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence
Amended Tender Offer Statement by Third Party